AI Summary
Thinking
Thinking
We reviewed 3 live results for therakos cellex and narrowed them down to the 3 options that look most worth comparing first.
The options are Therakos™ CELLEX™, THERAKOS® CELLEX® Photopheresis System and THERAKOS™ CELLEX™ Photopheresis System.
Source: Therakos
Description
Therakos CELLEX è un sistema di fotoferesi extracorporea (ECP) completamente integrato e certificato ai sensi del regolamento europeo MDR (UE 2017/745). Il dispositivo automatizza la raccolta cellulare, il calcolo del dosaggio di 8-MOP e la fotoattivazione UVA, operando con un percorso fluido sterile continuo a singolo o doppio ago. È indicato per il trattamento del linfoma cutaneo a cellule T (CTCL), il rigetto del trapianto di organi solidi e la malattia del trapianto contro l’ospite (GvHD).
Best for
professionisti sanitari, ematologi, trattamento di fotoferesi extracorporea ECP and gestione della GvHD e rigetto di trapianto
Rate this product
Source: Therakos
Description
The THERAKOS CELLEX Photopheresis System is an FDA-approved medical platform specifically designed for extracorporeal photopheresis administration. Developed for the palliative treatment of skin manifestations of Cutaneous T-Cell Lymphoma unresponsive to other therapies, it operates via single-needle or double-needle modes. The fully integrated closed system incorporates automated photosensitizing agent dosing calculations using UVADEX methoxsalen sterile solution, automated buffy coat collection, centrifuge cell separation, and UVA light photoactivation in both inpatient and outpatient healthcare environments.
Best for
Healthcare professionals, Oncologists, Extracorporeal photopheresis therapy and Palliative treatment of cutaneous T-cell lymphoma skin manifestations
Rate this product
Source: Therakos
Description
The THERAKOS CELLEX Photopheresis System is an integrated medical device designed for extracorporeal photopheresis (ECP) immunomodulation procedures. Featuring automated collection, photoactivation, and reinfusion within a single uninterrupted sterile fluid path, it offers single- and double-needle operation modes. Certified under EU Medical Device Regulation (EU MDR) 2017/745, the system is indicated for cutaneous T-cell lymphoma and solid organ transplant rejection in adults, as well as acute and chronic graft-versus-host disease in pediatric and adult patients aged three and older.
Best for
Healthcare professionals, Hospitals and photopheresis treatment centres, Extracorporeal photopheresis (ECP) therapy and Immunomodulation treatment for CTCL, solid organ transplant rejection, and GvHD
Rate this product
| Compare | #1Therakos™ CELLEX™ | #2THERAKOS® CELLEX® Photopheresis System | #3THERAKOS™ CELLEX™ Photopheresis System |
|---|---|---|---|
| Source | Therakos | Therakos | Therakos |
| Description | Therakos CELLEX è un sistema di fotoferesi extracorporea (ECP) completamente integrato e certificato ai sensi del regolamento europeo MDR (UE 2017/745). Il dispositivo automatizza la raccolta cellulare, il calcolo del dosaggio di 8-MOP e la fotoattivazione UVA, operando con un percorso fluido sterile continuo a singolo o doppio ago. È indicato per il trattamento del linfoma cutaneo a cellule T (CTCL), il rigetto del trapianto di organi solidi e la malattia del trapianto contro l’ospite (GvHD). | The THERAKOS CELLEX Photopheresis System is an FDA-approved medical platform specifically designed for extracorporeal photopheresis administration. Developed for the palliative treatment of skin manifestations of Cutaneous T-Cell Lymphoma unresponsive to other therapies, it operates via single-needle or double-needle modes. The fully integrated closed system incorporates automated photosensitizing agent dosing calculations using UVADEX methoxsalen sterile solution, automated buffy coat collection, centrifuge cell separation, and UVA light photoactivation in both inpatient and outpatient healthcare environments. | The THERAKOS CELLEX Photopheresis System is an integrated medical device designed for extracorporeal photopheresis (ECP) immunomodulation procedures. Featuring automated collection, photoactivation, and reinfusion within a single uninterrupted sterile fluid path, it offers single- and double-needle operation modes. Certified under EU Medical Device Regulation (EU MDR) 2017/745, the system is indicated for cutaneous T-cell lymphoma and solid organ transplant rejection in adults, as well as acute and chronic graft-versus-host disease in pediatric and adult patients aged three and older. |
| Best for | professionisti sanitari, ematologi, trattamento di fotoferesi extracorporea ECP and gestione della GvHD e rigetto di trapianto | Healthcare professionals, Oncologists, Extracorporeal photopheresis therapy and Palliative treatment of cutaneous T-cell lymphoma skin manifestations | Healthcare professionals, Hospitals and photopheresis treatment centres, Extracorporeal photopheresis (ECP) therapy and Immunomodulation treatment for CTCL, solid organ transplant rejection, and GvHD |
| Action | Therakos | Therakos | Therakos |
| Rate this product |
"Therakos™ CELLEX™ from Therakos."
Note: TopFind AI compiles product and service information for general comparison purposes only.